- James (Jim) Duffy and Greg Rhinehart Named Area Vice Presidents of Sales
- New leaders add significant spine-industry experience in building and leading dedicated sales
channels
CARLSBAD, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec
Holdings, Inc. (Nasdaq:ATEC), and a provider of spinal fusion technologies, announced today the addition of two new sales
executives with proven track records in the spine industry, naming James (Jim) Duffy as Area Vice President, U.S. Sales, South, and
Greg Rhinehart as Area Vice President, U.S. Sales, East. Drawing on their deep commercial spine experience, Messrs. Duffy and
Rhinehart will be responsible for expanding the Company’s presence in the Southern and Eastern United States, respectively,
including continuing to build dedicated sales agent relationships, targeting new customer and market opportunities, and
providing service and support for existing surgeon customers.
“I’m excited to welcome Jim and Greg to the Alphatec family as we continue to build out a strong sales
leadership team that is focused on driving sustainable growth and improving patient outcomes,” said Terry Rich, Alphatec Spine’s
Chief Executive Officer. “Jim and Greg bring tremendous track records to Alphatec and they will be instrumental in recruiting and
developing top distributors and sales talent to deepen our engagement with surgeons and build greater awareness and adoption of our
differentiated products. I look forward to working with both leaders as we accelerate our sales strategy and aggressively
work to become the fastest growing company in spine.”
Jim Duffy Named AVP Sales, South Region
Mr. Duffy brings over 25 years of progressive spine and orthopedic sales leadership experience to Alphatec,
including a proven history of building strong distributor relationships and dedicated distribution channels. Mr. Duffy joins
Alphatec from Zimmer Biomet Spine, where he was the Sales Vice President for the East region of the United States following
Zimmer’s merger with Biomet, and was responsible for the strategic integration and management of the distribution
channel. Prior to Zimmer Biomet, Mr. Duffy served as the Area Vice President of Sales for Zimmer Spine. Earlier
in his career, Mr. Duffy served in a number of district and regional sales leadership roles, including at KARL STORZ
Endoscopy-America, Medtronic Spinal and Biologics, and at Synthes Spine.
Mr. Duffy holds a Bachelor of Science in Business Management from Westfield State University.
Greg Rhinehart Named AVP Sales, East Region
With over two decades of spine and orthopedic sales leadership experience, Mr. Rhinehart brings significant
expertise to Alphatec in developing high-performing sales organizations, and driving expansion and revenue growth. Prior to
joining Alphatec, Mr. Rhinehart was the Vice President of Sales at Medicrea. Before that, Mr. Rhinehart held senior sales
leadership roles at Globus Medical, Inc., where he most recently served as the Vice President of Sales for the Central U.S.
region—a position he held for nine years. Under his leadership at Globus, Mr. Rhinehart successfully built a new sales
organization to continue Globus’ expansion in the Central U.S., significantly growing annual revenues. Prior to joining
Globus, Mr. Rhinehart held multiple sales leadership roles in spine and orthopedics at DePuy Spine, Medtronic, Sulzer-Spinetech and
DePuy Orthotech.
Mr. Rhinehart holds a Bachelor of Science in Business Administration from Ohio State University.
Inducement Awards Granted
As an inducement to entering into employment with the Company and in accordance with NASDAQ Listing Rule
5635(c)(4) under Alphatec Holdings Inc.’s 2016 Employment Inducement Award Plan (the “Plan”), on March 30, 2017, the Compensation
Committee of the Board of Directors of Alphatec Holdings, Inc. approved the following inducement awards:
- Mr. Duffy: 25,000 restricted stock units (RSUs) and an option to purchase 25,000 shares of common stock.
- Mr. Rhinehart: 25,000 restricted stock units (RSUs) and an option to purchase 25,000 shares of common stock.
The RSUs and stock options were granted pursuant to the Plan. Collectively, the RSUs and options were
granted as inducements material to the new employees entering into employment with Alphatec in accordance with NASDAQ Listing Rule
5635(c)(4).
The RSUs will vest in equal installments annually over four years on each of the first four anniversaries of the
first date of employment, which was March 31, 2017 for Mr. Rhinehart and April 4, 2017 for Mr. Duffy, assuming in each case the
employee remains continuously employed by Alphatec as of such vesting date. In addition, the RSUs will fully vest upon a change in
control of Alphatec.
The stock options will have an exercise price equal to the closing price per share of Alphatec’s common stock as
reported by NASDAQ on the date of grant (the first date of employment). The stock options will vest over four years, with 25% of
the options vesting on the first anniversary of the date of grant and the remainder of the options vesting monthly over the
subsequent three years, assuming in each case the employee remains continuously employed by Alphatec as of such vesting date. In
addition, the options will fully vest upon a change in control of Alphatec.
Alphatec is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Alphatec Spine
Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a medical device company that
designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with
disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements
in spinal fusion technologies. The Company markets products in the U.S. via independent sales agents and a direct sales force.
Additional information can be found at www.alphatecspine.com.
Forward Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations
and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results
or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result
of various factors. Forward-looking statements include the Company's ability to successfully expand in certain geographic
regions, launch new products, deepen surgeon engagement, build brand awareness and accelerate growth. The words "believe," "will,"
"should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify
forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. The
important factors that could cause actual operating results to differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to: the uncertainties in the Company's ability to execute upon its
strategic operating plan; the uncertainty of success in launching new products and developing new products or products currently in
the Company’s pipeline; the failure to achieve acceptance of the Company’s products by the surgeon community; continuation of
favorable third party payor reimbursement for procedures performed using the Company's products; the Company's ability to compete
with other competing products and with emerging new technologies; and the Company's ability to meet its financial obligations under
its credit agreements and the Orthotec settlement agreement. Please refer to the risks detailed from time to time in Alphatec
Holdings' SEC reports, including its Annual Report Form 10-K, as well as its other filings on Form 10-Q and periodic filings on
Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as
a result of new information, future events, or otherwise, unless required by law.
CONTACT: Investor/Media Contact: Christine Zedelmayer Investor Relations Alphatec Spine, Inc. (760) 494-6610 czedelmayer@alphatecspine.com
